News and updates from IPOX®, including media mentions, interviews, research and press releases.
Crypto exchange Bullish, backed by Peter Thiel, has upsized its IPO to target a $4.82B valuation. IPOX®’s Kat Liu says the pricing reflects trends of setting ranges below prior valuations, and stablecoin deployment will help accelerate infrastructure growth.
Reuters reports the Trump administration may launch IPOs for Fannie Mae and Freddie Mac this year, potentially valuing them at $500 billion. IPOX® VP Kat Liu cautions that a partial sale without a clear government exit plan could weigh on valuations, as investors may expect future sell-downs.
In a CNBC feature on the renewed momentum in space-related IPOs, IPOX® Research Associate Lukas Muehlbauer provided expert commentary on current market dynamics. He noted it is “definitely a good time for Space IPOs,” explaining that while government contracts provide insulation from tariffs, dependency on foreign components remains a vulnerability. Muehlbauer also highlighted how increased competition will lower entry barriers for new business models.
In a Reuters article covering Heartflow's upsized U.S. initial public offering, IPOX® Research Associate Lukas Muehlbauer provided expert analysis on the rebounding medtech IPO market. He noted that Heartflow's success "stands out, with the tightened price range indicating a well-covered book and strong demand," signaling positive momentum for the sector after a multi-year downturn.
In a Reuters article about Firefly Aerospace’s upsized IPO, IPOX® Research Analyst Lukas Muehlbauer provided expert commentary. He explained that the narrower price range signals “well-covered books on high demand and strong pricing conviction.” Muehlbauer also noted that potential rate relief should cushion volatility and allow the positive IPO market sentiment to continue into the fall.
In a Reuters report on Lummus Technology’s confidential IPO filing, IPOX® Research Associate Lukas Muehlbauer explained the firm's strategic appeal. He highlighted its high-margin revenue model from technology licensing and recurring royalties, positioning Lummus as an attractive alternative to capital-intensive energy operators that own heavy assets, especially given the current U.S. domestic energy push.
Discussing the rare IPO of exchange operator MIAX, IPOX® CEO Josef Schuster told Reuters there is “strong appetite for U.S. domiciled specialty IPOs.” He offered a balanced view, noting that while MIAX should benefit from this trend, its valuation could be impacted by the fact that it is “not a pure growth deal.”
Swedish financial outlet ETFMarknaden.se highlighted how investors can access the IPO market using the IPOX®-linked ETFs. The article explains these funds are designed to capture the early growth of newly listed firms, a phase traditional index funds often miss. It specifically identifies the IPOX®-linked First Trust U.S. (FPX) and European (IPXE) Equity Opportunities UCITS ETFs as key vehicles.
In a Reuters article covering the IPO of medtech firm Heartflow, IPOX® CEO Josef Schuster provided expert commentary on the upcoming listing. Schuster noted Heartflow's "strong top-line growth and high gross margins position it well for initial investor interest," but cautioned that "broader market volatility" could lead to investor caution beyond the first day of trading.